Acer therapeutics announces initiation of two investigator-sponsored trials of acer-801 (osanetant) in men with adenocarcinoma of the prostate

Posh-map and port-map investigator-sponsored trials to evaluate ability of acer-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer posh-map and port-map investigator-sponsored trials to evaluate ability of acer-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer
ACER Ratings Summary
ACER Quant Ranking